The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer by Dineen, Sean P et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Cancer
Open Access Research article
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that 
decreases tumor burden in an orthotopic mouse model of 
pancreatic cancer
Sean P Dineen1,2, Laura A Sullivan1,2, Adam W Beck1,2, Andrew F Miller1,2, 
Juliet G Carbon1,2, Roni Mamluk3, Henry Wong3 and Rolf A Brekken*1,3,4
Address: 1Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical School, Dallas, TX 75390-8593, USA, 
2Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical School, Dallas, TX 75390-8593, USA, 3Adnexus, a 
Bristol-Myers Squibb Company, Waltham, MA 02453, USA and 4Department of Pharmacology, University of Texas Southwestern Medical School, 
Dallas, TX 75390-8593, USA
Email: Sean P Dineen - SDINEE@parknet.pmh.org; Laura A Sullivan - laura.payton@utsouthwestern.edu; 
Adam W Beck - awbeck01@yahoo.com; Andrew F Miller - andyfmiller@gmail.com; Juliet G Carbon - juliet.carbon@utsouthwestern.edu; 
Roni Mamluk - roni@chiasmacorp.com; Henry Wong - hwong@adnexustx.com; Rolf A Brekken* - rolf.brekken@utsouthwestern.edu
* Corresponding author    
Abstract
Background: Pancreatic cancer continues to have a 5-year survival of less than 5%. Therefore, more effective therapies are
necessary to improve prognosis in this disease. Angiogenesis is required for tumor growth, and subsequently, mediators of
angiogenesis are attractive targets for therapy. Vascular endothelial growth factor (VEGF) is a well-characterized mediator of
tumor angiogenesis that functions primarily by binding and activating VEGF receptor 2 (VEGFR2). In this study, we evaluate the
use of CT-322, a novel biologic (Adnectin). This small protein is based on a human fibronectin domain and has beneficial
properties in that it is fully human, stable, and is produced in bacteria. CT-322 binds to and inhibits activation of VEGFR2.
Methods: The efficacy of CT-322 was evaluated in vivo using two orthotopic pancreatic tumor models. The first model was a
human tumor xenograft where MiaPaCa-2 cells were injected into the tail of the pancreas of nude mice. The second model was
a syngeneic tumor using Pan02 cells injected into pancreas of C57BL/6J mice. In both models, therapy was initiated once primary
tumors were established. Mice bearing MiaPaCa-2 tumors were treated with vehicle or CT-322 alone. Gemcitabine alone or in
combination with CT-322 was added to the treatment regimen of mice bearing Pan02 tumors. Therapy was given twice a week
for six weeks, after which the animals were sacrificed and evaluated (grossly and histologically) for primary and metastatic tumor
burden. Primary tumors were also evaluated by immunohistochemistry for the level of apoptosis (TUNEL), microvessel density
(MECA-32), and VEGF-activated blood vessels (Gv39M).
Results: Treatment with CT-322 was effective at preventing pancreatic tumor growth and metastasis in orthotopic xenograft
and syngeneic models of pancreatic cancer. Additionally, CT-322 treatment increased apoptosis, reduced microvessel density
and reduced the number of VEGF-activated blood vessels in tumors. Finally, CT-322, in combination with gemcitabine was safe
and effective at controlling the growth of syngeneic pancreatic tumors in immunocompetent mice.
Conclusion: We conclude that CT-322 is an effective anti-VEGFR2 agent and that further investigation of CT-322 for the
treatment of pancreatic cancer is warranted.
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Background
Pancreatic cancer continues to carry a poor prognosis,
with a 5-year survival rate of approximately five percent
[1]. As patients typically present at an advanced stage, new
chemotherapeutic strategies are necessary to improve the
dismal prognosis associated with this disease. Angiogen-
esis is a hallmark of cancer [2] and is required for cancer
growth beyond 1–2 mm3  [2,3]. Vascular endothelial
growth factor A (VEGF) is the best characterized member
of the VEGF family of growth factors. VEGF is a potent
angiogenic factor expressed during development and in
tumors [4,5]. The effects of VEGF are mediated by binding
to one of its two receptors VEGF receptor 1 or 2 (VEGFR1,
VEGFR2) [4,6]. Tumor angiogenesis is driven primarily by
VEGF:VEGFR2 interaction [5,6]. The effect of VEGFR1
activation is less understood, but is thought to be involved
in macrophage chemotaxis [5-7].
The complexity of the VEGF pathway allows for multiple
targets for inhibiting tumor angiogenesis [5,8]. For exam-
ple, bevacizumab (Avastin®, Genentech, Inc., South San
Francisco, CA) is a monoclonal antibody to human VEGF
which binds VEGF and blocks its interaction with both
VEGFR1 and VEGFR2 [9]. Bevacizumab has been shown
to be effective in combination with chemotherapy for the
treatment of metastatic colorectal cancer and non-small
cell lung cancer [10,11]. Receptor tyrosine kinase inhibi-
tors have also been developed which inhibit the VEGF
receptors [5,8]. These small molecules penetrate into cells
and, unlike antibodies, inhibit multiple members of the
VEGF receptor family. This broad spectrum of inhibition
may lead to different side effect profiles from monoclonal
antibodies [5].
There are a variety of proteins being developed as new bio-
logic drugs beyond the traditional biologic class of mon-
oclonal antibodies [12]. Adnectins are a new class of
targeted biologics among the most advanced of such pro-
teins. Adnectins are well-suited to pharmaceutical discov-
ery and development, based on preclinical data [13,14].
These small proteins are derived from the 10th type III
domain of human fibronectin, an extracellular protein
that is abundant in human serum and the extracellular
matrix, and naturally binds to other proteins [13,14]. By
changing the amino acid sequence of three targeting loops
clustered at one end of the protein, an Adnectin can be
designed to bind to a specific disease target, such as a
receptor, ligand or protein with nanomolar or picomolar
affinity, and potency and specificity comparable to or bet-
ter than antibodies. One such Adnectin has been devel-
oped that binds to VEGFR2. This construct, CT-322, has
been shown previously to block the activity of murine and
human VEGFR2 in vitro [13].
In the present study, we were interested in whether this
novel compound would block tumor angiogenesis and
subsequent growth in an orthotopic model of pancreatic
cancer. In the following experiments, we demonstrate that
CT-322 is effective at treating pancreatic tumors in two
animal models, that CT-322 blocks tumor angiogenesis
and that treatment with CT-322 induces tumor destruc-
tion.
Methods
Cell Lines and Culture
The human pancreatic carcinoma cell line MiaPaCa-2
(ATCC, Manassas, VA) and the murine cell line Pan02
also known as Panc02 (NCI, Frederick, MD) were main-
tained at 37°C in a mixture of 5% CO2 and 95% air in
Dulbecco's minimal essential medium (DMEM; Invitro-
gen, Carlsbad, CA) supplemented with 10% fetal calf
serum (Gimini Bio-Products, Woodland, CA). Cell sus-
pensions for tumor cell injection (TCI) were made by
removing cells from tissue culture flask with 0.2% trypsin.
The reaction was stopped with serum-containing DMEM.
Cells underwent centrifugation at 230 × g for 5 min and
the cell pellet was resuspended to the appropriate concen-
tration in PBS. Cell suspensions were used only if viability
exceeded 95% by trypan blue exclusion assay.
Animal Models
Athymic female nude mice were purchased from Charles
River (Wilmington, MA). Female C57BL/6J wild-type
mice were purchased from Jackson Laboratories (Bar Har-
bor, MA). Animals were housed with ad libitum access to
food and water in a pathogen free facility. All procedures
were performed in accordance with a protocol approved
by the Institutional Animal Care and Use Committee of
UT Southwestern (Dallas, TX).
Orthotopic tumors were established by injection of cells
directly into the pancreas as previously described [15].
Briefly, animals were anesthetized using 2–4% iso-
fluorane. The abdominal wall and peritoneum were
opened and the spleen and the tail of the pancreas were
identified and externalized through the wound. Tumor
cells were injected under the capsule the pancreas using a
30-gauge needle (2.5 × 105 Mia-PaCa-2 cells, 4 × 105
Pan02 cells, in 50 μl of PBS). The incision was closed with
a 5-0 prolene suture.
Treatment
In the xenograft model (MiaPaCa-2) therapy began 10
days after tumor cell injection (TCI). Therapy groups con-
sisted of control (vehicle provided by Adnexus, Waltham,
MA) and CT-322 (30 mg/kg, provided by Adnexus) in the
xenograft model. In the syngeneic model (Pan02) a gem-
citabine (3.5 mg/mouse) group and a combined CT-322
+ gemcitabine group were added. Therapy was given twiceBMC Cancer 2008, 8:352 http://www.biomedcentral.com/1471-2407/8/352
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weekly by intraperitoneal (i.p.) injection and was contin-
ued for six weeks. Animals were sacrificed at this time as
control mice developed lethargy and failure to properly
groom.
Immunohistochemistry
Tissue sections were either snap frozen in liquid nitrogen
or fixed in formalin (Sigma, St Louis, MO) and paraffin
embedded. Hematoxylin and eosin (H&E) staining was
done by the Molecular Pathology Core at UT Southwest-
ern (Dallas, TX). Paraffin embedded sections were first de-
paraffinized by heating to 60°C followed by xylene
immersion. Sections were re-hydrated with sequential
ethanol submersion. Non-specific binding was blocked
with 20% Aquablock (East Coast Biologics, North Ber-
wick, ME) for 30 minutes. Primary antibody (MECA-32
[16], Gv39M [17]) was added for one hour at room tem-
perature or overnight at 4°C and subsequently developed
with the appropriate secondary antibodies (Jackson
Immunoresearch Laboratories, West Grove, PA). TUNEL
analysis was done per manufacturer's recommendations
(Promega, Madison, WI). Immunofluorescent sections
were quantified using Nikon Elements imaging software
(Melville, NY).
Statistics
Data was collected into a spreadsheet program (Microsoft
Excel) and then imported into GraphPad (GraphPad
Prism version 4.00 for Windows; GraphPad Software, San
Diego CA, http://www.graphpad.com). Differences
between means of two groups were calculated using a
Mann-Whitney test; differences between three or more
groups were determined with non-parametric one-way
ANOVA (Kruskal-Wallis test) with Dunn's post test for
multiple comparisons. Statistical significance was estab-
lished as p < 0.05.
Results
CT-322 inhibits the growth of orthotopic MiaPaCa-2 
pancreatic tumors
To test whether direct inhibition of VEGFR2 with CT-322
inhibits pancreatic tumor growth, we used an orthotopic
model of pancreatic cancer. In this model, MiaPaCa-2
human pancreatic cancer cells were injected into the tail of
the pancreas of nude mice and tumors were allowed to
develop prior to treatment [15]. Therapy consisted of
vehicle control or CT-322 given twice weekly and was ini-
tiated ten days after tumor cell injection. At sacrifice,
tumor weights were measured. CT-322 reduced pancreatic
tumor growth by approximately 50% in this model (Fig
1). In this model CT-322 did not reduce metastatic events
and the incidence of metastasis was the same (8/9, 88%)
in the control and CT-322 treated animals and the mean
number of metastases was similar in both groups (1.7, CT-
322; 2.1, control).
CT-322 is effective in combination with gemcitabine in a 
syngeneic model of pancreatic cancer
One advantage of CT-322 compared to human mono-
clonal antibodies specific for VEGF or VEGFR2 is the fact
that CT-322 binds to both murine and human VEGFR2.
This allows for testing in a syngeneic model using immu-
nocompetent animals. Additionally in this experiment,
we tested the combination of CT-322 and gemcitabine,
the standard chemotherapy for pancreatic cancer. Tumors
were established in C57BL/6J mice using the murine pan-
creatic carcinoma cell line Pan02. Therapy was started one
week later and continued for 6 weeks. The combination of
CT-322 and gemcitabine was an effective therapeutic reg-
imen, reducing tumor growth by >50% (Fig 2). Both CT-
322 and gemcitabine alone decreased tumor growth, but
combination therapy had a greater effect and was the only
treatment group to reach statistical significance compared
to control-treated animals. Metastatic disease was assessed
by visual inspection of abdominal organs, lymph nodes
and lungs. In this model all treatment groups showed
decreased metastatic burden compared to control (Table
1).
CT-322 reduces microvessel density
VEGF inhibition is thought to exert anti-tumor effects in
part by inhibiting the development of blood vessels in the
tumor. To assess the effect of CT-322 on tumor angiogen-
esis, sections of tumor were analyzed by immunohisto-
chemistry with MECA-32, an antibody specific for mouse
CT-322 reduces tumor size in a xenograft model of pancre- atic cancer Figure 1
CT-322 reduces tumor size in a xenograft model of 
pancreatic cancer. Human MiaPaCa-2 tumors were estab-
lished in the tail of the pancreas in athymic nude mice. Ther-
apy was initiated 10 days after tumor cell injection. 
Treatment with the anti-VEGFR2 Adnectin CT-322 (30 mg/
kg) was given by i.p. injection twice weekly for 6 weeks (until 
sacrifice). Mean (+/- SEM) tumor weight at the time of sacri-
fice is displayed. CT-322 significantly reduced tumor size 
compared to control treated animals (Control 1.11 ± 0.17 g, 
CT-322 0.64 ± .010 g; n = 9 animals per group. *p < 0.05).BMC Cancer 2008, 8:352 http://www.biomedcentral.com/1471-2407/8/352
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endothelial cells. Treatment with CT-322 reduced tumor
microvessel density significantly in the MiaPaCa-2
xenograft model (Fig 3) and the Pan02 syngeneic model
(Fig 4).
Furthermore, CT-322 also decreased the level of VEGF-
activated blood vessels. VEGF binding to VEGFR2 medi-
ates the activation of endothelial cells and induces angio-
genesis [18]. An antibody that recognizes VEGF bound to
VEGFR (Gv39M) [17,19] was used to assess whether CT-
322 had an effect in vivo on the activation state of blood
vessels in MiaPaCa-2 tumors. As shown in figure 5A, there
were no blood vessels that were Gv39M positive following
CT-322 treatment, whereas approximately 30% of vessels
in the control treated animals were positive for a standard
endothelial cell marker (MECA-32) and Gv39M (Fig 5B).
Increased tumor destruction following CT-322 treatment
Routine hematoxylin and eosin staining demonstrated
that treatment of mice bearing orthotopic MiaPaCa-2
tumors with CT-322 resulted in a significant increase in
tumor necrosis (Fig 6A). Furthermore, treatment with CT-
322 induced a significant increase in the number of
TUNEL-positive cells in the tumor tissue compared to
control treated animals (Fig 6B).
Discussion
Pancreatic cancer remains a deadly disease, with a dismal
five year survival [1]. Contributing to the poor outcome is
the resistance or insensitivity of most pancreatic cancers to
chemotherapy. Gemcitabine, the current standard of care,
extends life only minimally. Therefore, novel therapeutics
agents are necessary to improve the survival associated
with this disease.
Angiogenesis has been described as both a hallmark of
cancer [2] and as an "organizing principle" around which
anti-cancer therapy can be developed [20]. VEGF is a key
mediator of tumor angiogenesis that functions primarily
through VEGFR2. The complexity of the VEGF signaling
pathway allows for multiple levels of inhibition, as seen
by the large number of lead compounds entering trials
that target this pathway [8,20]. One approach for VEGF
inhibition is to reduce the availability of ligand (VEGF), as
demonstrated by bevacizumab, a monoclonal antibody
specific for human VEGF [9]. This approach has been val-
idated in clinical trials combining chemotherapy and bev-
acizumab in the treatment of metastatic colorectal [10] or
breast cancer [21]. However, despite initially promising
results in pancreatic cancer, a subsequent randomized
controlled trial failed to show clinical benefit of combin-
ing bevacizumab with gemcitabine [22,23].
In this series of experiments, we chose to investigate a
novel anti-angiogenic agent. The Adnectin CT-322 binds
VEGFR2 and prevents activation of the receptor. This
approach is different than marketed tyrosine kinase inhib-
itors (e.g., sutent and sorafenib) in that CT-322 selectively
blocks VEGFR2 activation without affecting other recep-
tors or pathways. Additionally, the Adnectin compound
utilizes E. coli-based manufacturing methods, making it
well suited for clinical drug development.
Tumor size is reduced after CT-322 treatment in a syngeneic  model of pancreatic cancer Figure 2
Tumor size is reduced after CT-322 treatment in a 
syngeneic model of pancreatic cancer. Orthotopic 
murine Pan02 tumors were established in C57BL/6J wild-
type mice. Treatment twice weekly i.p. injections of CT-322 
(30 mg/kg), gemcitabine (3.5 mg/animal/injection) (GEM), or 
CT-322 (CT) + GEM was started 7 days after tumor cell 
injection and continued for 6 weeks, at which point animals 
were sacrificed. Mean (+/- SEM) tumor weight at the time of 
sacrifice is displayed. The combination treatment of CT-322 
and GEM significantly inhibited tumor growth (control 0.44 ± 
0.11 g, 0.153 ± 0.01 g; n = 8/group except CT+GEM n = 10; p 
< 0.05).
Table 1: Effect of therapy on metastatic burden in mice bearing 
Pan02 tumors
GROUP METASTASIS
Number Incidence (%)
Control 14 6/8 (75)
CT 0 0/8 (0)
GEM 0 0/8 (0)
CT+ GEM 0 0/10 (0)
Metastatic events in mice bearing orthotopic Pan02 tumors were 
evaluated by visual inspection of the liver, lungs, and entire 
gastrointestinal tract at the time of sacrifice.BMC Cancer 2008, 8:352 http://www.biomedcentral.com/1471-2407/8/352
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CT-322 reduces microvessel density in pancreatic cancer xenografts Figure 3
CT-322 reduces microvessel density in pancreatic cancer xenografts. MiaPaCa-2 tumor sections from animals 
treated with CT-322 or control were analyzed for microvessel density by immunohistochemistry using MECA-32. The mean 
(+/- SEM) number of blood vessels/high power field (total magnification, 400×) is displayed. The number of vessels in tumors 
from CT-322 treated animals was reduced compared to control (4.2 ± 4.7 versus 17.5 ± 4.7; 3 tumors per group, 3–5 high 
power fields per tumor; p = 0.001). Two representative pictures from each group are shown.BMC Cancer 2008, 8:352 http://www.biomedcentral.com/1471-2407/8/352
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VEGFR2 inhibition with CT-322 reduces microvessel density in a syngeneic model of pancreatic cancer Figure 4
VEGFR2 inhibition with CT-322 reduces microvessel density in a syngeneic model of pancreatic cancer. Frozen 
sections of tumors from mice treated with vehicle alone (Control), CT-322, gemcitabine (GEM), or the combination of CT-322 
+ gemcitabine were evaluated for microvessel density by immunohistochemistry using MECA-32. Representative images of 
MECA-32 immunohistochemistry are displayed along with the mean (+/- SEM) number of blood vessels/field (total magnifica-
tion, 200×). Microvessel density in Pan02 tumors from mice treated with CT-322 monotherapy was reduced compared to 
tumors from control-treated animals (control, 70.0 ± 3.6; CT-322, 52.6 ± 2.3; 3 tumors per group, at least 5 fields per tumor; 
*, p < 0.001 vs. control). Two representative pictures from each group are shown.BMC Cancer 2008, 8:352 http://www.biomedcentral.com/1471-2407/8/352
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VEGF-activated blood vessels are reduced after CT-322 treatment Figure 5
VEGF-activated blood vessels are reduced after CT-322 treatment. Immunohistochemistry using Gv39M, an antibody 
recognizing VEGF-activated blood vessels, and MECA-32 was performed on frozen sections of MiaPaCa-2 tumors from animals 
treated with control or CT-322. The percentage of MECA-32-positive blood vessels that were stained by Gv39M is displayed. 
Representative images of co-localization of MECA-32 (green) and Gv39M (red) is shown, magnification 200×. This represents 
two tumors per group, 8–10 high power fields, p < 0.05.BMC Cancer 2008, 8:352 http://www.biomedcentral.com/1471-2407/8/352
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The major finding of this study is that the adnectin CT-
322 effectively controls the growth of orthotopic pancre-
atic tumors in mice by reducing VEGF-induced angiogen-
esis. We evaluated the efficacy of CT-322 in xenograft
(MiaPaCa-2) and syngeneic (Pan02) tumors. As a single
agent CT-322 appears to be more effective in the xenograft
tumors where it reduced tumor growth by 50% whereas
growth was reduced by less than 25% in the syngeneic
model and was not different from tumors from control-
treated animals. It is worth pointing out that Pan02
tumors are more invasive locally than MiaPaCa-2 tumors
and often animals with Pan02 tumors need to be sacri-
ficed due to disease burden that is far smaller than what is
seen in xenograft models. For instance MiaPaCa-2 tumors
CT-322 causes tumor destruction Figure 6
CT-322 causes tumor destruction. A) Sections of MiaPaCa-2 tumors were fixed in formalin and paraffin embedded. H&E 
staining revealed homogenous histology in tumors from the control treated animals. In contrast tumors from CT-322 treated 
animals showed large areas of tumor destruction (*). Representative images from each group are shown. B) Formalin fixed par-
affin embedded MiaPaCa-2 tumor sections from animals treated with control or CT-322 were stained for TUNEL activity. The 
mean (+/- SEM) % of pixels above threshold is displayed. Treatment with CT-322 increased the number of TUNEL-positive 
apoptotic cells per tumor section (control 4.3 ± 2.03, CT-322 30.6 ± 6.9). Images were analyzed using Nikon Elements imaging 
software (2 tumors per group, 10 fields per tumor were analyzed, p < .001). Two representative pictures from each group are 
shown.BMC Cancer 2008, 8:352 http://www.biomedcentral.com/1471-2407/8/352
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from control-treated animals were on average over 1 g in
size whereas Pan02 tumors from control-treated animals
were on average just over 0.4 g in size. Thus it is possible
that the xenograft tumors are more dependent upon
VEGF-induced angiogenesis than the Pan02 tumors and
thus anti-VEGF strategies are more effective as standalone
agents in this setting.
We also observed in both tumor models that CT-322 as a
single agent reduced microvessel density. Interestingly,
Pan02 tumors from mice treated with CT-322 and gemcit-
abine did not show the same degree of reduction in
microvessel density as tumors from mice treated with CT-
322 alone. This is perplexing considering that the combi-
nation therapy was more effective at reducing overall
tumor size. One possible explanation is that not all the
blood vessels stained with MECA-32 are functional. In
future studies this could determined by intravenous injec-
tion of an endothelial cell marker (eg., tomato lectin) or a
fluorescent dye to track perfusion. An alternative non-
exclusive explanation is that a high percentage of the
blood vessels present in the tumors in the combination
treated group have been co-opted from normal pancreas
and are associated with pericytes and thus less sensitive to
anti-VEGF therapy. This is plausible given that the size of
the tumors is quite small in the combination treated
group. It is worth pointing out that the tumor weights
shown in figures 3 and 4 include residual normal pan-
creas, which typically weighs 0.1–0.15 g. It is difficult
especially in the Pan02 model to dissect the tumor from
the normal tissue due to the local invasion by the tumor.
Thus, especially in the syngeneic model we may be under-
estimating the efficacy of CT-322-based therapy.
CT-322 has begun clinical trials and initial results from
the first phase I studies were discussed recently at the 2008
American Society of Clinical Oncology meeting [24].
Thirty nine patients with solid tumors or non-Hodgkin's
lymphoma were enrolled. 2 mg/kg/week was determined
to be the maximum tolerated dose and out of 37 patients
evaluated 49% had stable disease. These are promising
results and have prompted a phase II study in combina-
tion with irinotecan in patients with recurrent glioblast-
ome multiforme [24].
Conclusion
Our results show that in two aggressive preclinical pancre-
atic cancer models, the strategy of selectively targeting
VEGFR2 with CT-322 is effective. This compound is exper-
imentally useful in that it blocks both mouse and human
VEGFR2, thus allowing us to demonstrate the effective-
ness of this drug in a fully immunocompetent mouse
model. We also show that CT-322 enhances the efficacy of
gemcitabine in this setting. As gemcitabine typically only
prolongs life by a few months, agents improving its effi-
cacy are needed. Further, these data demonstrate the
safety and therapeutic utility of the Adnectin platform and
suggest that further investigation of CT-322 is warranted
in both animal models and clinical trials.
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